Takeda Pharmaceutical Co Ltd: 143rd Interim Business Report Summary
Business Context and Reporting Period
This Form 6-K filing presents the 143rd Interim Business Report for Takeda Pharmaceutical Company Limited for the six-month period ended September 30, 2019. The report covers the first half of Fiscal Year 2019 (April 1, 2019 – September 30, 2019). A significant portion of the financial performance is driven by the acquisition of Shire, which closed on January 8, 2019, with Shire's results fully consolidated for this period.
Key Financial Metrics
| Metric (Billion JPY) | FY2018 H1 | FY2019 H1 | Change |
|---|---|---|---|
| Revenue | 880.6 | 1,660.2 | +88.5% |
| Operating Profit | 172.0 | 50.3 | -70.7% |
| Net Profit for the Period | 126.5 | 33.3 | -73.7% |
| Core Operating Profit | N/A | 541.6 | N/A |
| Underlying Core EPS | N/A | 249.25 JPY | N/A |
Liquidity and Balance Sheet (as of Sept 30, 2019):
- Cash and Cash Equivalents: 543.5 billion JPY (down from 702.1 billion JPY at March 31, 2019).
- Total Debt (Bonds and Loans): 5.02 trillion JPY (4.85 trillion non-current + 0.17 trillion current).
- Goodwill: 4.03 trillion JPY.
- Intangible Assets: 4.43 trillion JPY.
Material Changes vs. Prior Period
Revenue Growth: Revenue increased by 779.6 billion JPY (88.5%) primarily due to the inclusion of Shire products (contributing 767.5 billion JPY). Key growth drivers included:
- GI: ENTYVIO sales rose 31.2% to 168.4 billion JPY.
- Neuroscience: Revenue surged 360.5% to 213.9 billion JPY, largely due to VYVANSE (131.5 billion JPY) from the Shire portfolio.
- Rare Diseases: Shire products contributed 327.2 billion JPY, led by ADVATE (83.2 billion JPY) and ELAPRASE (35.5 billion JPY).
Profit Decline: Despite revenue growth, Operating Profit fell 70.7% to 50.3 billion JPY. This was driven by:
- Amortization: A 225.4 billion JPY increase in amortization and impairment losses, primarily 211.3 billion JPY related to Shire intangible assets.
- Integration Costs: Other operating expenses rose 410.4% due to 49.6 billion JPY in restructuring expenses for Shire integration.
- Cost of Sales: Increased 147.4% due to Shire inclusion and 137.8 billion JPY in non-cash charges (unwinding of fair value step-up on inventory).
Underlying Performance: On an underlying basis (excluding currency, divestitures, and non-recurring items), revenue growth was flat (-0.2%). However, Underlying Core Operating Profit Margin improved to 32.2% due to cost synergies and the Global Opex Initiative.
Guidance, Outlook, and Risks
Revised FY2019 Forecast (Announced Oct 31, 2019):
- Revenue: Revised down to 3,260.0 billion JPY (from 3,300.0 billion JPY) due to foreign exchange headwinds (yen appreciation) and the NATPARA recall.
- Operating Profit: Revised up to a loss of 110.0 billion JPY (from a loss of 166.0 billion JPY), reflecting higher Core Operating Profit and revised purchase accounting assumptions.
- Net Profit: Revised up to a loss of 273.0 billion JPY (from a loss of 367.7 billion JPY), aided by a 56.3 billion JPY non-cash deferred tax benefit from Swiss Tax Reform.
- Core Operating Profit: Revised up to 930.0 billion JPY.
Management Commentary & Risks:
- NATPARA Recall: In September 2019, NATPARA was recalled in the U.S. due to a rubber septum issue, negatively impacting Rare Metabolic revenue.
- Divestitures: Takeda completed the divestiture of XIIDRA in July 2019 and expects to complete the divestiture of TACHOSIL within FY2019.
- Dividend: An interim dividend of 90 JPY per share was approved, payable December 2, 2019. The annual dividend policy remains 180 JPY per share.
Key Facts for Investor Verification
- Shire Integration Impact: Verify the sustainability of cost synergies and the timeline for full integration benefits, as integration costs significantly impacted reported operating profit.
- Amortization Charges: Confirm the magnitude of non-cash amortization expenses related to Shire intangible assets, which heavily suppressed reported earnings.
- NATPARA Recall Resolution: Monitor the status of the NATPARA recall and its long-term impact on the Rare Metabolic portfolio revenue.
- Underlying vs. Reported Metrics: Distinguish between reported GAAP results (heavily impacted by acquisition accounting) and underlying non-GAAP metrics (flat revenue growth, strong core margins) to assess operational health.
- Foreign Exchange Sensitivity: Assess the impact of the strengthening Yen on future revenue forecasts, as FX was a primary driver for the downward revenue revision.